Safety and Efficacy of Pallidal or Subthalamic Nucleus Stimulation in Advanced PD
Neurol 56:548-551, Volkmann,J.,et al, 2001
Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations
AJNR 37:774-781, Winton-Brown, T.T.,et al, 2016
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Opiates and Synthetic Analgesic Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1201, Ropper, A.H.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Sedative-Hypnotic Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1206, Ropper, A.H.,et al, 2014
Natalizumab-Associated PML Identified in the Presymptomatic Phase Using MRI Surveillance
Neurol 78:507-508, Blair,N.F.,et al, 2012
Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008
The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005
Transient Lesion in the Splenium of the Corpus Callosum and Antiepileptic Drug Withdrawal
Neurol 65:1032-1036, Gurtler,S.,et al, 2005
Trihexyphenidyl Withdrawal Encephalopathy
Ann Neurol 41:133-134, Johkura,K.,et al, 1997